Prashant Kumar: Privileged to present an incredible data on Novel Cancer Vaccine PerCVax
Prashant Kumar, Chief Scientific Officer at Adjunct Professor at
“It was an incredibly memorable moment to present in front of the Nobel Laureate Prof James Allison. It was both Exhilarating and Inspiring!
Prof Allison groundbreaking work in the discovery of the role of CTLA-4 in regulating immune response has indeed revolutionised Cancer Treatment. His contributions have inspired a whole generation of researchers to explore and redefine immunotherapeutic approaches.
Privileged to present an incredible data on Novel Cancer Vaccine, PerCVax. Kudos to the Datar Cancer Genetics Limited extraordinary team and Mr RAJAN DATAR, a prodigy who guided to this transformative approach of POLYVALENT ANTIGENIC approach in Vaccine Development. The advancement in Vaccine are pushing the boundaries of Cancer Immunotherapy. I truly believe that PercVax will reshape cancer management by shifting the focus from treating Advanced disease to Prevention, early intervention, and durable Immune Responses.
Thanks to Dr Sewanti Limaye, A PRECISION GODDESS at Sir H.N. Reliance Foundation Hospital & Research Centre for giving me this platform to present our work!
She is the leader who tailors treatment and transform lives!!!
I great opportunity to meet greatest minds Massimo Cristofanilli, Herbert Loong, Anil Sood Sangeeta Goswami, Shaheenah Dawood and a dear friend Sachet Shukla.
Also got an opportunity to meet friends and leaders Sanjeeva Srivastava, Aju Mathew, Richa Chauhan, Soumil Vyas, Dr. Shweta Bansal, Dr. Darshana Patil and many others who are shaping the future of medicine!”
“We are on a relentless mission to destroy technical barriers and re-define cancer treatment for better outcomes. We share with humility and delight a significant milestone in our journey towards developing Per-C-Vax, our novel cancer vaccine. After rigorous cell line, in-vitro and animal studies, we have very successfully completed the preclinical phase, bringing us one step closer to clinical translation.
Our Chief Scientific Officer Dr. Prashant Kumar presented the preclinical data at the Illuminate Conference organised by the Reliance Foundation Hospital, Mumbai, where we engaged with leading experts in the field, gained valuable insights, and received encouraging feedback on our work.
As we gear up for the next phase, we remain committed to pushing the boundaries of cancer immunotherapy and translating science into meaningful impact.
A big thank you to our incredible team, collaborators, and everyone who has supported us in this journey. Stay tuned for more updates!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023